FDA 483 - Wells Pharma of Houston LLC - April 14, 2026

Wells Pharma of Houston LLC, an outsourcing facility in Texas, was inspected by the FDA between March 17 and April 13, 2026. The inspection revealed several critical safety and quality control concerns that potentially compromise the sterility and efficacy of compounded drugs. Primary violations included poor aseptic practices, such as technicians failing to properly disinfect equipment and wearing inadequate protective gear that left skin and hair exposed near sterile workspaces. Airflow studies designed to prove a contamination-free environment were also found to be flawed. Additionally, the company lacked scientific justification for the shelf-life assigned to products like Cefazolin. Testing often showed the drugs failed to meet quality standards well before their expiration dates, yet the facility adjusted specifications rather than addressing the stability issues. Further issues involved the release of products tested with incorrect methods and a significant lack of control over medication labels, which were stored in unsecured cabinets—a recurring problem from previous inspections. The Quality Control Unit also failed to oversee documentation properly, frequently using obsolete forms and failing to thoroughly investigate errors. Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act, these observations suggest that products may have been prepared under insanitary conditions. Wells Pharma is required to submit a formal response to the FDA detailing their corrective actions to address these deficiencies. Failure to rectify these issues could lead to further regulatory enforcement.